|
Advanced Life Sciences Holdings, Inc. - Comparative Business Analysis Snapshot
Business Description
Advanced Life Sciences Holdings, Inc.. The Group's principal activities are discovering, developing and commercializing novel drugs for infectious disease, inflammation and oncology. The Group has license from Abbott Laboratories to develop and commercialize cethromycin, a novel ketolide antibiotic in Phase III clinical development for the treatment of respiratory tract infections. It is also developing ALS-886, a novel therapeutic in preclinical development for the treatment of inflammation-related tissue damage, including tissue damage associated with acute respiratory distress syndrome and ALS-357, a compound that has shown anti-tumor activity against malignant melanoma in preclinical trials.
Competitor Analysis
This analysis compares Advanced Life Sciences Holdings, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
